PFS as a surrogate for overall survival in metastatic melanoma
A partir d'une revue de la littérature des essais de phase III pour le traitement d'un mélanome métastatique (12 essais identifiés, 4 416 patients au total), cette méta-analyse évalue la corrélation entre un critère de jugement de substitution, la survie sans progression, et la survie globale
For decades, overall survival has been the primary endpoint for most phase 3 trials in melanoma. Overall survival is the most objective and convenient measure of meaningful clinical efficacy of investigational drugs, provided no serious flaws are present in the trial design. The absence of effective anticancer drugs for melanoma made assessment of overall survival an obvious choice for the primary endpoint of phase 3 studies, at least until recently...
The Lancet Oncology , commentaire, 2013